Therefore, this study better fills this gap, suggesting that in the context of the widespread use of trastuzumab, HER2 positivity alone can still be regarded as a risk factor for premenopausal HR+ breast cancer, and all HR+/HER2+ patients are recommended to accept endocrine therapy including OFS. This evidence concerns the gene ERBB2 and breast carcinoma.